Coherus BioSciences Q2 2024 Adj. EPS $(0.14) Beats $(0.29) Estimate, Sales $65.000M Beat $61.366M Estimate
Author: Benzinga Newsdesk | August 08, 2024 04:21pm
Coherus BioSciences (NASDAQ:
CHRS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.29) by 51.72 percent. The company reported quarterly sales of $65.000 million which beat the analyst consensus estimate of $61.366 million by 5.92 percent. This is a 10.70 percent increase over sales of $58.716 million the same period last year.
Posted In: CHRS